GLP-1

Weight loss concept
#GLP-1 #Metabolic diseases #MetaVia #Obesity #Phase I trial #Weight loss

Statistically significant PhI results for GLP-1/glucagon dual agonist

MetaVia has announced positive statistically significant results from the eight-week, non-titrated 48mg, multiple ascending dose (MAD) cohort of its Phase I clinical trial of DA-1726.  DA-1726 is a novel, dual oxyntomodulin (OXM) analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for… Read More

#News

#GLP-1 #Ozempic #UCL #Weight loss

1.6 million UK patients used weight loss drugs in past year 

An estimated 1.6 million adults in England, Wales and Scotland used weight loss drugs in the past year, new findings suggest.  The study, led by researchers at University College London, showed 1.6 million adults used drugs including Wegovy and Mounjaro to help lose weight between early 2024 and early 2025. Read More

#News

FDA
#FDA #GLP-1 #Novo Nordisk #Obesity #Weight loss

FDA approves first oral GLP-1 for weight management

The US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.  The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy… Read More

#News #Regulatory #Trending News

#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Oral GLP-1 helps patients maintain weight loss after injectables

Lilly’s orforglipron has helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase III trial.  The ATTAIN-MAINTAIN trial evaluated orforglipron, a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks… Read More

#Editor's Choice #News

#GLP-1 #Mergers and acquisitions #Pfizer #Weight loss

Pfizer boosts weight loss pipeline with GLP-1 drug

Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of ShangAhai Fosun Pharmaceutical, for the development, manufacturing and commercialisation of YP05002.  YP05002 is a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase I development for chronic weight management.  “We look forward… Read More

#Business & Investment #News

#Business #GLP-1 #Obesity #PrecisionLife

Test could trigger reimbursement for obesity drugs 

Patients could soon be reimbursed for ineffective anti-obesity drugs after human omics company Ovation and precision medicine company PrecisionLife partnered to develop a first-of-its-kind test.  The collaboration between the companies aims to develop drug-response biomarkers for glucagon-like peptide-1 receptor agonist (GLP-1) therapies. The resulting findings could form the basis… Read More

#News

#Alzheimer's #GLP-1 #Neurodegenerative disorders #Novo Nordisk #Obesity

Semaglutide shows no benefit in Alzheimer’s disease

Novo Nordisk has revealed that its Phase III trials of semaglutide (the active ingredient in Ozempic and Wegovy) did not demonstrate a statistically significant reduction in Alzheimer's disease progression.  The top-line results from the two-year primary analysis of evoke and evoke+ Phase III trials in early-stage symptomatic Alzheimer’s disease were… Read More

#Business & Investment #News #Trending News

#Dementia #GLP-1 #Lupus #Menopause

DDW Highlights: 4 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s top story came from women’s health, as Bayer paved the way for… Read More

#Podcasts

#Dementia #GLP-1 #Lupus #Menopause #Weight loss

This week in Drug Discovery (27 – 31 October)

News round-up for 27 – 31 October by Bruno Quinney, Content Team at DDW.  Women’s health is top of this week’s agenda, as Bayer paves the way for a new approach to treat hot flashes due to menopause. Elsewhere, an anti-obesity medication has health benefits beyond weight… Read More

#News

Patient injects Ozempic
#Diabetes #GLP-1 #Innovent #Phase III trial #Weight loss

Mazdutide shows superiority to semaglutide in a head-to-head trial

In the Phase III DREAMS-3 clinical trial of mazdutide, the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist showed superior efficacy to semaglutide for body weight reduction.  In Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide performed better than semaglutide on the primary endpoint,… Read More

#News #Trending News

Ozempic (semaglutide)
#Cardiovascular disease #GLP-1 #Novo Nordisk #University College London

Semaglutide protects heart beyond weight loss benefits

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, says a new study led by University College London (UCL).  The finding, the researchers say, suggests there are multiple ways the drug… Read More

#News #Trending News

Human liver
#FDA #Fibrosis #GLP-1 #Liver disease #Novo Nordisk

Wegovy granted accelerated approval in the US for liver disease

The US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4mg) as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).  The approval is in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet… Read More

#News #Regulatory #Trending News

Weight loss concept
#GLP-1 #GPCRs #Nxera Pharma #Obesity #Weight loss

Nxera unveils obesity and chronic weight management pipeline

Biopharmaceutical company Nxera Pharma has launched a broad new pipeline strategically focused on advancing therapies for obesity and associated metabolic disorders.  Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline… Read More

#News

Mounjaro
#Cardiovascular disease #Diabetes #Eli Lilly #GLP-1 #Obesity

Mounjaro comes out on top in head-to-head trial

Lilly has shared topline results from SURPASS-CVOT, a head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.   Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed… Read More

#News

#Diabetes #GLP-1 #Mass spectrometry / NMR #Weight loss

How mass spectrometry is supporting GLP-1 breakthroughs in diabetes care

Kean Woodmansey, Senior Global Market Development Manager, Discovery (DMPK), SCIEX, examines how molecular precision is being enabled in GLP-1 therapies through the use of mass spectrometry. On Diabetes Alert Day in March, professionals across healthcare, research, and pharmaceutical development reflected on the pressing need for improved diabetes detection and treatment. Read More

#Exclusive Content #Trends & Analysis

Weight loss concept
#GLP-1 #Metabolic diseases #Obesity #Protagonist Therapeutics #Weight loss

Triple agonist designed to outperform GLP-1 drugs for obesity

Protagonist Therapeutics has announced a new, highly potent oral triple agonist peptide development candidate for obesity.   With once-daily dosing, PN-477o targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors.  The company has announced it will also develop a subcutaneous version, PN-477sc, as… Read More

#News